ClinicalTrials.gg
CompletedNCT05566639Updated Jan 16, 2025Results posted

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

A Phase 3 interventional study of mRNA-1010 and Fluarix Quadrivalent in Seasonal Influenza, sponsored by ModernaTX, Inc.. Completed at 233 sites in 11 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22,502
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.

Enrollment
2nd of 12
22,502 · median 471
Started
2022
with 5 others
Phase 3
4 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
12 of 12
ModernaTX, Inc.

Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 2nd largest by enrollment, is one of 6 that started in 2022, is one of 4 in phase 3, and was the 5th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About mRNA-1010 influenza vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.

03

Conditions studied

  • Seasonal Influenza

Browse trials for

Keywords

  • Flu
  • Influenza
  • Vaccine
  • mRNA vaccine
  • mRNA-1010
  • Moderna
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Investigator has assessed that the participant understands and is willing and physically able to comply with protocol mandated follow-up, including all procedures.

    • For female participants of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose on Day 1, and agreement to continue adequate contraception through 90 days following vaccine administration.

Exclusion criteria

Exclusion Criteria:

  • Participant has had close contact with someone with laboratory-confirmed influenza infection or with someone who has been treated with antiviral therapies for influenza (for example, Tamiflu®) within the past 5 days prior to the Screening visit.
  • Participant has had close contact to someone with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or COVID-19 as defined by the US CDC or has had a positive SARS-CoV-2 test in the past 10 days prior to the Screening visit.
  • Participant is acutely ill or febrile (temperature ≥38.0℃elcius [100.4°Fahrenheit]) 72 hours prior to or at the Screening visit or Day 1. Participants meeting this criterion may be rescheduled within the 28-day screening window.
  • Participant has a history of a diagnosis or condition that, in the judgment of the investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.
  • Reported history of congenital or acquired immunodeficiency, immunocompromising/ condition, asplenia, or recurrent severe infections.
  • Reported history of anaphylaxis or severe reaction after receipt of any mRNA or influenza vaccines or any components of the mRNA or influenza vaccines, including egg protein.
  • Participant has received systemic immunosuppressant drugs for >14 days in total within 180 days prior to the Screening visit (for glucocorticosteroids, ≥10 milligrams (mg)/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study. Inhaled, nasal, and topical are allowed.
  • Participant has received any vaccine authorized or approved by local health agency ≤28 days prior to study intervention (Day 1) or plans to receive a vaccine authorized or approved by local health agency within 28 days before or after the study intervention.
  • Participant is unaware whether they have received an influenza vaccine in the previous influenza season.
  • Participant received a seasonal influenza vaccine or any other influenza vaccine within 180 days prior to Day 1
  • Participant has tested positive for influenza by local health authority-approved testing methods within 180 days prior to Day 1.
  • Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening visit or plans to donate blood products during the study.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
22,502 participants (actual)

Study arms

  • Experimental
    mRNA-1010

    Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.

    Biological: mRNA-1010

  • Active comparator
    Fluarix Quadrivalent

    Participants will receive a single dose of Fluarix Quadrivalent by IM injection on Day 1.

    Biological: Fluarix Quadrivalent

Interventions

  • BiologicalmRNA-1010

    Sterile liquid for injection

    Also known as: Seasonal influenza vaccine

  • BiologicalFluarix Quadrivalent

    Sterile suspension for injection.

    Also known as: Licensed quadrivalent inactivated seasonal influenza vaccine

06

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)

    Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: 7 days post-vaccination

  2. Number of Participants With Unsolicited Adverse Events (AEs)

    An unsolicited AE was an AE that was not solicited using a participant diary and that was communicated by a participant who has signed the informed consent. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure.

    Time frame: Up to 28 days post-vaccination

  3. Number of Participants With Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Discontinuation

    An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or coronavirus disease 2019 \[COVID-19\] and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (Day 361) are reported in this outcome measure.

    Time frame: Day 1 through Day 361 (Month 12)

  4. Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined Influenza-Like Illness (ILI) Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine

    Protocol-defined ILI: The presence of body temperature ≥37.5 degrees celsius (°C) (≥99.5 degrees fahrenheit \[°F\]), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive Reverse Transcription Polymerase Chain Reaction (RT-PCR) for influenza.

    Time frame: 14 days post-vaccination through Day 181 (Month 6)

Secondary outcomes

  1. Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined ILI Caused by Influenza A or B Strains With Similarity to Those Selected for the Seasonal Vaccine

    Protocol-defined ILI: The presence of body temperature ≥37.5°C (≥99.5°F), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive RT-PCR for influenza.

    Time frame: 14 days post-vaccination through Day 181 (Month 6)

  2. Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined ILI Caused by Influenza A or B Strains Antigenically Matched to the Vaccine Strains Selected for the Seasonal Vaccine

    Protocol-defined ILI: The presence of body temperature ≥37.5°C (≥99.5°F), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive RT-PCR for influenza.

    Time frame: 14 days post-vaccination through Day 181 (Month 6)

  3. Number of Participants With First Episode of RT-PCR Confirmed United States (US) Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Influenza A or B Strains

    CDC-defined ILI: The presence of temperature ≥37.8°C \[≥100°F\], accompanied by at least one of the respiratory illness symptoms (cough and/or sore throat) and a positive RT-PCR for influenza.

    Time frame: 14 days post-vaccination through Day 181 (Month 6)

  4. Number of Participants With First Episode of RT-PCR CDC-Defined ILI Caused by Influenza A or B Strains With Similarity to Vaccine Strains

    CDC-defined ILI: The presence of temperature ≥37.8°C \[≥100°F\], accompanied by at least one of the respiratory illness symptoms (cough and/or sore throat) and a positive RT-PCR for influenza.

    Time frame: 14 days post-vaccination through Day 181 (Month 6)

  5. Number of Participants With First Episode of RT-PCR CDC-Defined ILI Caused by Influenza A or B Strains That Were Antigenically Matched to Vaccine Strains

    CDC-defined ILI: The presence of temperature ≥37.8°C \[≥100°F\], accompanied by at least one of the respiratory illness symptoms (cough and/or sore throat) and a positive RT-PCR for influenza.

    Time frame: 14 days post-vaccination through Day 181 (Month 6)

  6. Number of Participants With First Episode of Culture-Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine

    Protocol-defined ILI: The presence of body temperature ≥37.5°C (≥99.5°F), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive RT-PCR for influenza.

    Time frame: 14 days post-vaccination through Day 181 (Month 6)

  7. Number of Participants With First Episode of Culture-Confirmed CDC-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine

    CDC-defined ILI: The presence of temperature ≥37.8°C \[≥100°F\], accompanied by at least one of the respiratory illness symptoms (cough and/or sore throat) and a positive RT-PCR for influenza.

    Time frame: 14 days post-vaccination through Day 181 (Month 6)

  8. Number of Participants With Hospitalizations Associated With RT-PCR Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine

    Protocol-defined ILI: The presence of body temperature ≥37.5°C (≥99.5°F), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive RT-PCR for influenza.

    Time frame: 14 days post-vaccination through Day 181 (Month 6)

  9. Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-matched Influenza A and B Strains

    Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% confidence interval (CI) was calculated based on the t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation.

    Time frame: Day 29

  10. Percentage of Participants Reaching Seroconversion at Day 29, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains

    Seroconversion was defined as either a Baseline HAI titer \<1:10 and a post-Baseline titer ≥1:40 or a Baseline HAI titer ≥1:10 and a minimum 4-fold rise in post-Baseline HAI antibody titer.

    Time frame: Day 29

  11. Percentage of Participants With HAI Titer ≥ 1:40 at Day 29

    Time frame: Day 29

  12. Geometric Mean Fold Rise (GMFR) of Anti-HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains

    The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

    Time frame: Baseline, Day 29

07

Results

Posted Jan 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneFluarix QuadrivalentmRNA-1010
Started1125011252
Full analysis set1119911211
Safety set1120011210
Solicited safety set1116011168
Per-protocol (pp) set1102611055
Pp immunogenicity set (ppis)408444
Completed1035910359
Not completed891893
Withdrew: Adverse event11
Withdrew: Serious adverse event13
Withdrew: Death4445
Withdrew: Lost to follow-up467461
Withdrew: Physician decision4544
Withdrew: Protocol deviation44
Withdrew: Withdrawal by subject277271
Withdrew: Other than specified5264

Outcome measures

PrimaryNumber of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)

Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
7 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
ParticipantsFluarix QuadrivalentmRNA-1010
Any56207989
Grade 138404433
Grade 215353050
Grade 3245500
Grade 406
PrimaryNumber of Participants With Unsolicited Adverse Events (AEs)

An unsolicited AE was an AE that was not solicited using a participant diary and that was communicated by a participant who has signed the informed consent. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure.

Time frame:
Up to 28 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events (AEs)
ParticipantsFluarix QuadrivalentmRNA-1010
Number of Participants With Unsolicited Adverse Events (AEs)14951351
PrimaryNumber of Participants With Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Discontinuation

An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or coronavirus disease 2019 \[COVID-19\] and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (Day 361) are reported in this outcome measure.

Time frame:
Day 1 through Day 361 (Month 12)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Discontinuation
ParticipantsFluarix QuadrivalentmRNA-1010
SAEs495518
AESIs1310
MAAEs31663126
AEs Leading to Discontinuation4749
PrimaryNumber of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined Influenza-Like Illness (ILI) Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine

Protocol-defined ILI: The presence of body temperature ≥37.5 degrees celsius (°C) (≥99.5 degrees fahrenheit \[°F\]), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive Reverse Transcription Polymerase Chain Reaction (RT-PCR) for influenza.

Time frame:
14 days post-vaccination through Day 181 (Month 6)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined Influenza-Like Illness (ILI) Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine
ParticipantsFluarix QuadrivalentmRNA-1010
Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined Influenza-Like Illness (ILI) Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine142140
Statistical analysis
  • Fluarix Quadrivalent vs mRNA-1010 · Stratified Cox proportional hazards · p = 0.1715 · Relative vaccine efficacy (rve): 1.7 · 95% CI -24.1 to 22.2rVE = 100 \* (1 - HR) % was defined as the percent reduction in the hazard (mRNA-1010 vs active comparator), where HR was the hazard ratio between mRNA-1010 vs the active comparator.
SecondaryNumber of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined ILI Caused by Influenza A or B Strains With Similarity to Those Selected for the Seasonal Vaccine

Protocol-defined ILI: The presence of body temperature ≥37.5°C (≥99.5°F), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive RT-PCR for influenza.

Time frame:
14 days post-vaccination through Day 181 (Month 6)

No measurements were reported for this outcome.

SecondaryNumber of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined ILI Caused by Influenza A or B Strains Antigenically Matched to the Vaccine Strains Selected for the Seasonal Vaccine

Protocol-defined ILI: The presence of body temperature ≥37.5°C (≥99.5°F), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive RT-PCR for influenza.

Time frame:
14 days post-vaccination through Day 181 (Month 6)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined ILI Caused by Influenza A or B Strains Antigenically Matched to the Vaccine Strains Selected for the Seasonal Vaccine
ParticipantsFluarix QuadrivalentmRNA-1010
Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined ILI Caused by Influenza A or B Strains Antigenically Matched to the Vaccine Strains Selected for the Seasonal Vaccine8575
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed United States (US) Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Influenza A or B Strains

CDC-defined ILI: The presence of temperature ≥37.8°C \[≥100°F\], accompanied by at least one of the respiratory illness symptoms (cough and/or sore throat) and a positive RT-PCR for influenza.

Time frame:
14 days post-vaccination through Day 181 (Month 6)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed United States (US) Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Influenza A or B Strains
ParticipantsFluarix QuadrivalentmRNA-1010
Number of Participants With First Episode of RT-PCR Confirmed United States (US) Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Influenza A or B Strains7070
SecondaryNumber of Participants With First Episode of RT-PCR CDC-Defined ILI Caused by Influenza A or B Strains With Similarity to Vaccine Strains

CDC-defined ILI: The presence of temperature ≥37.8°C \[≥100°F\], accompanied by at least one of the respiratory illness symptoms (cough and/or sore throat) and a positive RT-PCR for influenza.

Time frame:
14 days post-vaccination through Day 181 (Month 6)

No measurements were reported for this outcome.

SecondaryNumber of Participants With First Episode of RT-PCR CDC-Defined ILI Caused by Influenza A or B Strains That Were Antigenically Matched to Vaccine Strains

CDC-defined ILI: The presence of temperature ≥37.8°C \[≥100°F\], accompanied by at least one of the respiratory illness symptoms (cough and/or sore throat) and a positive RT-PCR for influenza.

Time frame:
14 days post-vaccination through Day 181 (Month 6)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR CDC-Defined ILI Caused by Influenza A or B Strains That Were Antigenically Matched to Vaccine Strains
ParticipantsFluarix QuadrivalentmRNA-1010
Number of Participants With First Episode of RT-PCR CDC-Defined ILI Caused by Influenza A or B Strains That Were Antigenically Matched to Vaccine Strains4438
SecondaryNumber of Participants With First Episode of Culture-Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine

Protocol-defined ILI: The presence of body temperature ≥37.5°C (≥99.5°F), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive RT-PCR for influenza.

Time frame:
14 days post-vaccination through Day 181 (Month 6)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of Culture-Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine
ParticipantsFluarix QuadrivalentmRNA-1010
Number of Participants With First Episode of Culture-Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine9181
SecondaryNumber of Participants With First Episode of Culture-Confirmed CDC-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine

CDC-defined ILI: The presence of temperature ≥37.8°C \[≥100°F\], accompanied by at least one of the respiratory illness symptoms (cough and/or sore throat) and a positive RT-PCR for influenza.

Time frame:
14 days post-vaccination through Day 181 (Month 6)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of Culture-Confirmed CDC-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine
ParticipantsFluarix QuadrivalentmRNA-1010
Number of Participants With First Episode of Culture-Confirmed CDC-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine4540
SecondaryNumber of Participants With Hospitalizations Associated With RT-PCR Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine

Protocol-defined ILI: The presence of body temperature ≥37.5°C (≥99.5°F), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive RT-PCR for influenza.

Time frame:
14 days post-vaccination through Day 181 (Month 6)
Reported as:
Count of participants · Participants
Number of Participants With Hospitalizations Associated With RT-PCR Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine
ParticipantsFluarix QuadrivalentmRNA-1010
Number of Participants With Hospitalizations Associated With RT-PCR Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine33
SecondaryGeometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-matched Influenza A and B Strains

Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% confidence interval (CI) was calculated based on the t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation.

Time frame:
Day 29
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-matched Influenza A and B Strains
titerFluarix QuadrivalentmRNA-1010
Influenza A H1N1 Antibody105.34 (95.71 to 115.93)149.14 (135.47 to 164.19)
Influenza A H3N2 Antibody85.99 (77.64 to 95.23)104.06 (94.35 to 114.77)
Influenza B/ Yamagata Lineage140.50 (127.49 to 154.85)132.24 (121.25 to 144.23)
Influenza B/ Victoria Lineage176.63 (162.42 to 192.08)139.91 (129.71 to 150.91)
SecondaryPercentage of Participants Reaching Seroconversion at Day 29, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains

Seroconversion was defined as either a Baseline HAI titer \<1:10 and a post-Baseline titer ≥1:40 or a Baseline HAI titer ≥1:10 and a minimum 4-fold rise in post-Baseline HAI antibody titer.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Seroconversion at Day 29, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains
percentage of participantsFluarix QuadrivalentmRNA-1010
Influenza A H1N1 Antibody29.4 (25.03 to 34.09)44.8 (40.13 to 49.58)
Influenza A H3N2 Antibody39.7 (34.93 to 44.64)52.0 (47.27 to 56.76)
Influenza B/ Yamagata Lineage27.5 (23.18 to 32.06)26.6 (22.52 to 30.95)
Influenza B/ Victoria Lineage22.8 (18.81 to 27.18)13.1 (10.07 to 16.56)
SecondaryPercentage of Participants With HAI Titer ≥ 1:40 at Day 29
Time frame:
Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With HAI Titer ≥ 1:40 at Day 29
percentage of participantsFluarix QuadrivalentmRNA-1010
Influenza A H1N1 Antibody90.0 (86.61 to 92.69)94.4 (91.80 to 96.32)
Influenza A H3N2 Antibody85.5 (81.75 to 88.81)89.6 (86.42 to 92.31)
Influenza B/ Yamagata Lineage94.6 (91.95 to 96.59)94.8 (92.33 to 96.69)
Influenza B/ Victoria Lineage98.3 (96.50 to 99.31)98.0 (96.19 to 99.07)
SecondaryGeometric Mean Fold Rise (GMFR) of Anti-HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains

The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

Time frame:
Baseline, Day 29
Reported as:
Geometric mean · ratio
Geometric Mean Fold Rise (GMFR) of Anti-HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains
ratioFluarix QuadrivalentmRNA-1010
Influenza A H1N1 Antibody2.42 (2.22 to 2.64)3.42 (3.13 to 3.73)
Influenza A H3N2 Antibody3.04 (2.79 to 3.30)3.74 (3.44 to 4.07)
Influenza B/ Yamagata Lineage2.46 (2.26 to 2.69)2.28 (2.14 to 2.43)
Influenza B/ Victoria Lineage2.07 (1.92 to 2.24)1.75 (1.65 to 1.85)

Adverse events

Collected over Day 1 up to the end of the study (Day 361). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluarix Quadrivalent44/11,250 (0.4%)495/11,200 (4.4%)603/11,200 (5.4%)
mRNA-101045/11,252 (0.4%)518/11,210 (4.6%)572/11,210 (5.1%)
Most frequent serious events
Showing 10 of 532
Most frequent serious events
EventFluarix QuadrivalentmRNA-1010
OsteoarthritisMusculoskeletal and connective tissue disorders22/1120012/11210
PneumoniaInfections and infestations21/1120021/11210
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders14/1120019/11210
Cerebrovascular accidentNervous system disorders14/1120016/11210
Atrial fibrillationCardiac disorders14/1120016/11210
Acute kidney injuryRenal and urinary disorders14/1120012/11210
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)12/112004/11210
Pulmonary embolismRespiratory, thoracic and mediastinal disorders12/112008/11210
SepsisInfections and infestations9/1120012/11210
Acute myocardial infarctionCardiac disorders11/1120012/11210
Most frequent other events
Most frequent other events
EventFluarix QuadrivalentmRNA-1010
COVID-19Infections and infestations603/11200572/11210

Baseline characteristics

Randomization Set included all participants who were randomized, regardless of the participant's treatment status in the study.

Age, Continuous
Age, Continuous(years)Fluarix QuadrivalentmRNA-1010Total
Mean63.8 ± 8.4163.9 ± 8.3663.9 ± 8.39
Sex: Female, Male
Sex: Female, Male(Participants)Fluarix QuadrivalentmRNA-1010Total
Female6281625612537
Male496949969965
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Fluarix QuadrivalentmRNA-1010Total
Hispanic or Latino183718593696
Not Hispanic or Latino9289927318562
Unknown or Not Reported124120244
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Fluarix QuadrivalentmRNA-1010Total
American Indian or Alaska Native5557112
Asian280254534
Native Hawaiian or Other Pacific Islander151126
Black or African American198619503936
White8790885017640
More than one race374885
Unknown or Not Reported8782169
08

Study locations

233 sites
  • North Alabama Research Center, LLC
    Athens, Alabama 35611, United States
  • Lenzmeier Family Medicine
    Glendale, Arizona 85308, United States
  • CCT Research
    Phoenix, Arizona 85044, United States
  • Fiel Family and Sports Medicine/CCT Research
    Tempe, Arizona 85283, United States
  • Noble Clinical Research
    Tucson, Arizona 85712, United States
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72204, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Velocity Clinical Research, Banning
    Banning, California 92220, United States
  • Hope Clinical Research, LLC
    Canoga Park, California 91303, United States
  • Marvel Clinical Research
    Huntington Beach, California 92647, United States
  • Velocity Clinical Research, Chula Vista
    La Mesa, California 91942, United States
  • Velocity Clinical Research, San Diego
    La Mesa, California 91942, United States
  • Velocity Clinical Research - Westlake
    Los Angeles, California 90057, United States
  • Empire Clinical Research
    Pomona, California 91767, United States
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
  • Benchmark Research-Texas
    Riverside, California 92504-3206, United States
  • Peninsula Research Associates (PRA)
    Rolling Hills Estates, California 90274, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Women's Health Care Research Corp.
    San Diego, California 92111, United States
  • Acclaim Clinical Research
    San Diego, California 92120, United States
  • Medical Center for Clinical Research
    San Diego, California 92120, United States
  • Shawn K Hassler MD
    San Francisco, California 94102-3014, United States
  • West Coast Research LLC
    San Ramon, California 94582, United States
  • Velocity Clinical Research, Denver
    Denver, Colorado 80209, United States
  • Arthritis & Rheumatology - Clinic of Northern Colorado
    Fort Collins, Colorado 80528, United States
  • Longmont Medical Research Network
    Longmont, Colorado 80501, United States
  • Nature Coast Clinical Research, LLC - Crystal River
    Crystal River, Florida 34429, United States
  • Floridian Clinical Research
    Hialeah, Florida 33016, United States
  • Homestead Associates in Research,Inc
    Hialeah, Florida 33016, United States
  • Broward Research Group
    Hollywood, Florida 33024, United States
  • Citrus Cardiology Consultants
    Inverness, Florida 34452, United States
  • Encore Research Group-Jacksonville Center for Clinical Resea
    Jacksonville, Florida 32216, United States
  • Health Awareness, Inc
    Jupiter, Florida 33458, United States
  • Multi-Therapeutic Research Associates, Inc.
    Lake City, Florida 32055, United States
  • Accel Research Sites - Lakeland
    Lakeland, Florida 33805, United States
  • ARS - Meridien Research
    Maitland, Florida 32751, United States
  • Global Health Research Center
    Miami Lakes, Florida 33016, United States
  • South Florida Research Center, Inc.
    Miami, Florida 33135, United States
  • Suncoast Research Associates Trials, LLC
    Miami, Florida 33135, United States
  • Miami centre of clinical research
    Miami, Florida 33155, United States
  • Clinical Trials of Florida, LLC
    Miami, Florida 33186, United States
  • Innovation Medical Research Center,inc
    Palmetto Bay, Florida 33157, United States
  • New Tampa Health, Inc
    Tampa, Florida 33603, United States
  • Tekton Research, Inc.
    Chamblee, Georgia 30341, United States
  • Southeast Regional Research Group
    Columbus, Georgia 31904, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • In-Quest Medical Research
    Norcross, Georgia 30092-4544, United States
  • Mount Vernon Clinical Research
    Sandy Springs, Georgia 30328, United States
  • Meridian Clinical Research - Savannah
    Savannah, Georgia 31406-2675, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281-9054, United States
  • Velocity Clinical Research - Boise
    Meridian, Idaho 83642, United States
  • Great Lakes Clinical Trials LLC
    Chicago, Illinois 60625, United States
  • Great Lakes Clinical Trials LLC
    Chicago, Illinois 60640, United States
  • Great Lakes Clinical Trials LLC
    Gurnee, Illinois 60031, United States
  • Chicago Health Medical Group
    River Forest, Illinois 60305, United States
  • Velocity Clinical Research - Valparaiso
    Valparaiso, Indiana 46385, United States
  • Meridian Clinical Research - Dakota Dunes
    Sioux City, Iowa 51106, United States
  • Johnson County Clin-Trials (JCCT)
    Lenexa, Kansas 66219, United States
  • Heartland Research Associates LLC
    Newton, Kansas 67114-9017, United States
  • Alliance for Multispecialty Research
    Wichita, Kansas 67207, United States
  • Meridian Clinical Research
    Baton Rouge, Louisiana 70809, United States
  • MedPharmics
    Covington, Louisiana 70433, United States
  • Medpharmics, LLC
    Metairie, Louisiana 70006, United States
  • Nathan H Fischman MD LLC
    New Orleans, Louisiana 70124, United States
  • Privia Medical Group
    Annapolis, Maryland 21401, United States
  • Rockville Internal Medicine Group
    Rockville, Maryland 20854-2957, United States
  • Delricht Research
    Springfield, Massachusetts 65807-7303, United States
  • DM Clinical Research - Detroit
    Southfield, Michigan 48076, United States
  • Paul G Matherne MD
    Biloxi, Mississippi 39531, United States
  • DELRICHT RESEARCH at GULFPORT MEMORIAL
    Gulfport, Mississippi 39503, United States
  • Sundance Clinical Research, LLC
    Saint Louis, Missouri 63141, United States
  • National Medical University and Embryonic Tissues Center EmC
    Springfield, Missouri 65802, United States
  • Montana Medical Research, Inc
    Missoula, Montana 59808, United States
  • CCT Research at Skyline Medical Center, PC
    Elkhorn, Nebraska 68022, United States
  • CCT Research / Methodist Physicians Clinic, Prairie Fields Family Medicine, PC
    Fremont, Nebraska 68025-2592, United States
  • Meridian Clinical Research
    Grand Island, Nebraska 68803, United States
  • Be Well Clinical Studies, LLC
    Lincoln, Nebraska 68516, United States
  • Medpace, Inc. - Clinical Pharmacology Unit (CPU)
    Norfolk, Nebraska 68701, United States
  • Meridian Clinical Research
    Norfolk, Nebraska 68701, United States
  • Papillon Research Centre
    Omaha, Nebraska 68130, United States
  • Meridian Clinical Research - Omaha
    Omaha, Nebraska 68134, United States
  • Midwest Regional Health Services, LLC/CCT Research
    Omaha, Nebraska 68144-5225, United States
  • CCT Research
    Las Vegas, Nevada 89102-1682, United States
  • Clinical Research Center of Nevada LLC
    Las Vegas, Nevada 89104, United States
  • Santa Rosa Medical Centers of Nevada/ CCT Research
    Las Vegas, Nevada 89119, United States
  • Las Vegas Clinical Trials, LLC
    North Las Vegas, Nevada 89030, United States
  • United Medical Associates
    Binghamton, New York 13901-1043, United States
  • Rochester Clinical Research, Inc
    Rochester, New York 14609, United States
  • Velocity Clinical Research - Syracuse
    Syracuse, New York 13057, United States
  • Tryon Medical Group
    Charlotte, North Carolina 28210, United States
  • Carolina Institute for Clinical Research
    Fayetteville, North Carolina 28303, United States
  • Diabetes & Endocrinology Consultants
    Morehead City, North Carolina 28557, United States
  • M3 Wake Research, Inc.
    Raleigh, North Carolina 27612, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Trial Management Associates
    Wilmington, North Carolina 28403, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Radiant Research
    Akron, Ohio 44311, United States
  • Sterling Research Group
    Cincinnati, Ohio 45219, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45227, United States
  • Velocity Clinical Research - Cincinnati
    Cincinnati, Ohio 45242, United States

Showing the first 100 of 233 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jan 2024, 15 months.

Results were first posted in Jan 2025, 1 year after primary completion.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 15 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2022
First posted
Oct 4, 2022
StartActual
Sep 14, 2022
Primary completionActual
Jan 5, 2024
CompletionActual
Jan 5, 2024
Results first posted
Jan 16, 2025
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05566639
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Oct 4, 2022
Start date
Sep 14, 2022
Primary completion
Jan 5, 2024
Completion
Jan 5, 2024
Results posted
Jan 16, 2025
Last update
Jan 16, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1010 influenza vaccine

Start the discussion